Investigators Seek to Boost Surgical Cures in RCC With Immune Priming

Rachel Narozniak
Published: Thursday, Jul 18, 2019
Mohamad Allaf, MD

Mohamad Allaf, MD

In the phase III PROSPER trial (NCT03055013), investigators will attempt a novel approach in localized renal cell carcinoma (RCC): priming the immune system prior to nephrectomy with neoadjuvant nivolumab (Opdivo) and continuing with adjuvant blockade. The study will be the first to combine neoadjuvant and adjuvant immunotherapy with standard of care (SOC) nephrectomy.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x